BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zappulo E, Nicolini LA, Di Grazia C, Dominietto A, Lamparelli T, Gualandi F, Caligiuri P, Bruzzone B, Angelucci E, Viscoli C, Mikulska M. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab. Infection 2019;47:59-65. [PMID: 30232604 DOI: 10.1007/s15010-018-1214-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, Kao JH, Terrault N, Lok AS, Reddy KR. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol 2022;77:1670-89. [PMID: 35850281 DOI: 10.1016/j.jhep.2022.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Brakenhoff SM, Hoekstra R, Honkoop P, Roomer R, den Hollander JG, Bezemer G, de Knegt RJ, Sonneveld MJ, de Man RA. Patients treated with rituximab are poorly screened for hepatitis B infection: Data from a low-incidence country. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.11.024] [Reference Citation Analysis]
3 Zappulo E, Buonomo AR, Moccia M, Pinchera B, Villari R, Petracca M, Lanzillo R, Scotto R, Carotenuto A, Viceconte G, Moriello NS, Bruno L, Gentile I, Morra VB. Impact of an anti-infective screening and monitoring protocol together with Infectious Disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for Multiple Sclerosis. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Niu JX, Xu Y, Wu DP. [Progress in the research of HBV reactivation in patients undergoing hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2021;42:348-52. [PMID: 33979984 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.016] [Reference Citation Analysis]
5 Wu Y, Huang H, Luo Y. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:610500. [PMID: 33613534 DOI: 10.3389/fimmu.2020.610500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 He LY, Wang YL, Tian X, Chen WQ. The association of hepatitis B virus screening and antiviral prophylaxis with adverse liver outcomes in Chinese cancer patients undergoing chemotherapy: A retrospective study. Medicine (Baltimore) 2020;99:e19647. [PMID: 32243396 DOI: 10.1097/MD.0000000000019647] [Reference Citation Analysis]
7 Buzo BF, Ramos JF, Marques Rossetti RA, Salles N, Mendrone-Júnior A, Rocha V, de Seixas Santos Nastri AC. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center. Transpl Infect Dis 2020;22:e13243. [PMID: 31901206 DOI: 10.1111/tid.13243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Gentile G, Antonelli G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019;11. [PMID: 31717647 DOI: 10.3390/v11111049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
9 Ciclosporin/methylprednisolone. Reactions Weekly 2019;1745:93-93. [DOI: 10.1007/s40278-019-59256-x] [Reference Citation Analysis]